{"id":"W4412436457","doi":"10.1016/j.mayocpiqo.2025.100642","title":"Immunogenicity and Safety of ChAdOx1 nCoV-19 (AZD1222) as a Homologous Fourth-Dose Booster: A Substudy of the Phase 3 COV003 Trial in Brazil","year":2025,"lang":"en","type":"article","venue":"Mayo Clinic Proceedings Innovations Quality & Outcomes","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"Fundação Lemann; University of Oxford; AstraZeneca","keywords":"Immunogenicity; Medicine; Booster (rocketry); Coronavirus disease 2019 (COVID-19); Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); 2019-20 coronavirus outbreak; Booster dose; Coronavirus Infections; Virology; Pandemic; Betacoronavirus; Immunology; Internal medicine; Immunization; Infectious disease (medical specialty); Antigen; Aerospace engineering; Disease; Outbreak","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001869013,0.0003723971,0.0006562631,0.0001171072,0.0001824981,0.0003871211,0.0002956148,0.0003359723,0.001165482],"category_scores_gemma":[0.001560455,0.0001566025,0.00073667,0.0002033496,0.000319431,0.0002355152,0.0001730334,0.0006925242,0.000213912],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007907083,"about_ca_system_score_gemma":0.001045121,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003442083,"about_ca_topic_score_gemma":0.008500803,"domain_scores_codex":[0.9993882,0.0003864762,0.00003995221,0.00005989924,0.00005927393,0.00006611923],"domain_scores_gemma":[0.9991069,0.0001976938,0.0003326969,0.0001309736,0.00009821594,0.0001335044],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.4196153,0.01733335,0.1506891,0.002677826,0.00715521,0.0002895964,0.001136594,0.003152361,0.09351587,0.0004974258,0.004791595,0.2991457],"study_design_scores_gemma":[0.2095973,0.4255182,0.3269845,0.0005203199,0.004019047,0.0007104045,0.0004139853,0.002394813,0.01708207,0.0003849745,0.01231362,0.00006073402],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.99615,0.001832673,0.0002469523,0.0001885625,0.00001804865,0.0003113653,0.0003889038,0.00001349319,0.0008499513],"genre_scores_gemma":[0.9978499,0.0007058167,0.0003032413,0.0001498026,0.00002366259,0.0002137245,0.0004764844,0.000004917892,0.0002723458],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003442083,"threshold_uncertainty_score":0.009884357,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08267067014050773,"score_gpt":0.4710121085129448,"score_spread":0.3883414383724371,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}